Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high-risk patients in non-ICU, but not ICU, settings.
The clinical performance of several scores to predict VTE risk in the setting of malignancy are compared in a study.
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation.
Overall, 92.3 percent of patients had plasma D-dimer levels ≥0.05 µg/mL, including all with and 91.2 percent without, pulmonary embolism.
Long-term risks and consequences are considerable for patients receiving VKA, DOAC after first unprovoked VTE.
Researchers characterized incidence and factors linked to cerebral venous thrombosis associated with myeloproliferative neoplasms.
The authors review 8 cases of thrombosis in uncommon sites caused by protein S deficiency.
This first report on the safety of selective intracoronary hypothermia is a novel therapy that may reduce myocardial reperfusion injury in STEMI that has had demonstrated efficacy in animal model studies.
While cardiovascular disease may be common and commonly known to patients, they may not know some of the surprising factors in their diet and medical history that may actually be putting them at risk. What are some of the cardiovascular disease risk factors patients should know about?
Mortality seen in association with vaccine-induced immune thrombocytopenia and thrombosis (VITT) after the first dose of the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca) is increased for those with cerebral venous sinus thrombosis and a low platelet count.